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SIRT1 inhibition facilitates elimination of CML stem cells by Imatinib, in part via p53 activation. In this issue of
Cell StemCell, Li et al. (2014) demonstrate a similar role for SIRT1 inhibition in eradicating FLT3-ITDAML stem
cells, potentially through a positive feedback loop with c-MYC, highlighting SIRT1 as a potential target in
combination cancer therapy.Histone deacetylases (HDACs) are evolu-
tionarily conserved transcriptional core-
pressors that are frequently deregulated
in various humancancers (West and John-
stone, 2014). In addition to their well-
recognized histone modification function
involved in epigenetic regulation, HDACs
also remove acetyl groups from a variety
of nonhistone protein substrates critical
for normal and disease development. Un-
like class I/II/IV Zn2+-dependent HDACs,
class III HDACs comprising seven
mammalianmembersof theSirtuinprotein
family require NAD+ as a cofactor that
links transcriptionwith energymetabolism
(Barneda-Zahonero and Parra, 2012).
While the role of Sirtuins in oncogenesis
varies based on tissue type (Brooks and
Gu, 2009), recent evidence revealed a crit-
ical function for SIRT1 in regulating p53
activities in chronic myeloid leukemia
(CML) (Li et al., 2012). In contrast to pan-
HDAC inhibitors, genetic inactivation of
SIRT1 or administration of the Sirtuin in-
hibitor Tenovin-6 (TV6) appears to be
more tolerable to normal stem cells, and
applying it as a treatment in combination
with theBCR-ABL tyrosine kinase inhibitor
(TKI) Imatinib can help to eradicate CML
stem cells in mouse models, highlighting
its potential as a therapeutic target for
cancer stem cells. To gain further insights
into the role of SIRT1 in other hematologi-
cal malignancies, Li et al. (2014) now
extend their findings to acute myeloid leu-
kemia (AML) and propose a mechanism
involving a positive feedback loop be-
tween SIRT1 and c-MYC in regulating
AML stem cells (Figure 1).
In their current study published in this
issue of Cell Stem Cell, Li et al. (2014)
report that CD34+ cells fromAMLpatientswith intermediate to poor prognosis, and
in particular those carrying the FLT3-ITD
mutation, expressed high levels of SIRT1
protein and were particularly sensitive to
the SIRT1 inhibitor TV6. FLT3-ITD stabi-
lized SIRT1 protein levels, leading to
reduced p53 target gene expression.
Conversely, shRNA-mediated knock-
down or pharmacological inhibition of
SIRT1 in FLT3-ITD AML cells resulted in
an increased level of acetylated p53 and
its target gene expression, leading to an
effective killing of FLT3-ITD-expressing
cells, but not FLT3-WT or normal CD34+
cells, in vitro. More interestingly, inhibition
of SIRT1 also enhanced the effects of
FLT3 tyrosine kinase inhibitor Quizartinib
(AC220) in suppressing FLT3-ITD AML.
In spite of its effective inhibition of FLT3
kinase activity in FLT3-ITD AML cells,
AC220 only partially reduced SIRT1 and
p53 levels without significantly affecting
p53 acetylation or its target gene expres-
sion. In contrast to the modest inhibition
of primary FLT3-ITD CD34+ cells by
AC220 in vitro, a combination treatment
using TV6 and AC220 significantly
reduced oncogenic potential of FLT3-
ITD leukemic cells in vitro, in vivo, and in
secondary xenograft transplant, suggest-
ing an enhanced targeting of primitive
AML stem cells by SIRT1 inhibition.
Gene expression analysis, which was
performed to provide insight into the un-
derlying mechanism on FLT3-ITD AML
patient samples, revealed a significant
enrichment of c-MYC gene sets, which
might be activated via STAT5-induced
PIM kinase that phosphorylates and stabi-
lizes c-MYC. c-MYC knockdown led to
SIRT1 loss, whereas overexpression of
c-MYC resulted in SIRT1 deubiquitination,Cell Stem Cell 1which could be suppressed by USP22
deubiquitinase knockdown. Consistently,
USP22 expression could be induced by
c-MYC or FLT3-ITD. Intriguingly, SIRT1
knockdown or TV6 treatment reciprocally
increasedc-MYCacetylation and reduced
its stability and activity in FLT3-ITD AML
cells, suggesting the presence of a posi-
tive feedback loop between c-MYC and
SIRT1. The effective clearance of c-MYC
upon AC220 and TV6 combination treat-
ment may also explain the enhanced effi-
cacy as compared with single agents in
targetingFLT3-ITDAMLstemcells. There-
fore, this report has not only extended the
potential therapeutic application of SIRT1
inhibition in combination therapy to target
cancer stemcells in a different hematolog-
ical malignancy, it also reveals an underly-
ing mechanism involving a positive feed-
back loop that regulates c-MYC/SIRT1
functions. This model is also compatible
with the recent findings by Sasca et al.
(2014) showing a potentially parallel
FLT3/SIRT1 regulatory pathway mediated
by ATMandDBC1 that both converge into
the p53 pathway, which, when taken
together, provide multiple interception
points for therapeutic intervention in
FLT3-mutated AML (Figure 1A).
Although FLT3 is one of the most
common mutations found in AML, the
heterogeneity of AML in which different
subgroups are characterized by the pres-
ence of distinct genetic and cytogenetic
aberrations/mutations that directly im-
pact patient’s prognosis and response
to treatment (Zeisig et al., 2012) raises
questions about the role of FLT3 mutation
in disease development. In the case of
common translocation leukemia involving
MLL, CBF, or RARA fusions, FLT35, October 2, 2014 ª2014 Elsevier Inc. 395
Figure 1. Molecular Regulation and Targeting of SIRT1 in AML
(A) Proposed pathways and potential therapeutic intervention involving SIRT1 and its downstream effectors (e.g. p53 and c-MYC) in FLT3-ITD AML. The right arm
of the diagram based on the study by Li et al. (2014) shows that FLT3-ITD activates c-MYC via STAT5 and PIM1 kinase. c-MYC expression in turn enhances
expression of the deubiquitinase USP22 that stabilizes SIRT1 protein by protecting SIRT1 from proteasomal degradation. While a high level of SIRT1 expression
leads to a reduced activity of p53 by deacetylation of p53, it also stabilizes c-MYC. On the left arm of the diagram, based on the study by Sasca et al. (2014), both
ATM and DBC1 are dephosphorylated in the presence of FLT3-ITD. DBC1, inhibiting SIRT1 by binding to its catalytic domain, has much reduced binding affinity
to SIRT1 when it is dephosphorylated, leading to enhanced SIRT1 activity. Both studies show that FLT3-ITD AML subgroups can be targeted with FLT3-TKI and
iSIRT1 (SIRT1 inhibitor).
(B) Genetic and cellular heterogeneity influence the efficacy of SIRT1 inhibition and its therapeutic strategy in AML treatment. The current study from Li et al.
demonstrates that targeting SIRT1 in combination with FLT3-TKI can be an effective treatment avenue in NK-AML with FLT3-ITD (first panel). Combination ther-
apy with iSIRT1 and FLT3-TKI may be much less effective in NK-AML where the FLT3-ITD mutation does not occur at the pre-LSC level but only later during the
clonal evolution resulting in only a subset of leukemic cells harboring FLT3-ITD (second panel). In translocation AML (e.g., 11q23 translocations carrying MLL
fusions), where chimeric fusion proteins represent strong initiating events at the pre-LSC level, FLT3-ITD may only be acquired later during clonal evolution. Tar-
geting these subsets of AML with iSIRT and FLT3-TKI may not be effective (third panel). It is hypothesized that these subgroups of AML may be more efficiently
targeted by combination treatment of iSIRT1/FLT3-TKI and other agents that target the initiating events (e.g., iDOT1L that suppresses a critical component of the
MLL fusion transcriptional complex in 11q23 leukemia) (fourth panel).
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Previewsmutation might represent one of the
important cooperating events, but not
the dominant initiating driver (Figure 1B).
Similarly, even in normal karyotype (NK)
AML, where the FLT3 mutation can also
exist just in subclones (Ding et al., 2012;
Welch et al., 2012), FLT3/SIRT1 inhibition
may only be effective in targeting a sub-
set of AML stem cells in the patients
(Figure 1B). This may explain the failure
to eradicate FLT3-ITD+ AML stem cells
in both primary and secondary transplan-
tation models using the AC220 and TV6
combination treatment by the authors.
Although the study by Li et al. has not
investigated common translocation leuke-
mia, the report by Sasca et al. using well-396 Cell Stem Cell 15, October 2, 2014 ª201established primary murine models of
MLL-AF9 or AML1-ETO with FLT3-ITD
demonstrated rather modest in vitro ef-
fects from SIRT1 inhibition. Therefore it is
very likely that the effect of SIRT1 inhibi-
tion in FLT3-ITD+ AML will largely depend
on the dominant driver mutations and the
architecture of the leukemic clones. It is
tempting to speculate that SIRT1 inhibi-
tion in combination with other agents tar-
geting the initiating event may be an
attractive therapeutic avenue in certain
AMLsubsets (Figure 1B). To further realize
the therapeutic potentials, future studies
are needed to determine the efficacy of
combination treatments involving SIRT1
inhibition on various AML subtypes before4 Elsevier Inc.one can potentially translate these find-
ings into patients’ benefits. In addition,
the putative tumor suppressor functions
of SIRT1 (Wang et al., 2008) also need to
be carefully considered for any clinical
treatments. Nevertheless, the discovery
of the critical role of SIRT1 in mediating
oncogenic potentials of FLT3-ITD opens
up a new opportunity to improve the effi-
cacy of targeting FLT3-mutated AML.REFERENCES
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Aberrant neural crest (NC) development is at the origin of many congenital diseases. Given the limitations
in human NC cell isolation and expansion, the development of new strategies for NC generation is crucial.
In this issue of Cell Stem Cell, Kim et al. (2014) report the direct reprogramming of postnatal fibroblasts
into multipotent NC cells.Neural crest (NC) cells occupy a unique
position among stem cell populations
found in the embryo. First, the NC innova-
tion was a crucial event in vertebrate
evolution by making possible the devel-
opment of paired sense organs and, with
the development of NC-derived jaws, the
transition to a more predatory life style.
Second, the NC has one of the broadest
differentiation potentials in vivo, sur-
passed only by the inner cell mass of
the blastocyst (Bronner and LeDouarin,
2012). As a consequence, anomalous
NC development is at the root of many
congenital diseases including cranio-
facial, cardiovascular, and bowel syn-
dromes (Takahashi et al., 2013). Aberrant
NC biology has also been associated
with cancer originating from NC-derived
tissues, such as melanoma, the most
aggressive skin cancer (Shakhova et al.,
2012). Understanding how NC cells
develop and generate their distinct prog-
eny is thus highly relevant. In this issue
of Cell Stem Cell, Kim and colleagues
report the direct reprogramming of post-
natal fibroblasts into induced neural crest
cells (iNCCs). This approach constitutesan excellent platform to investigate NC
biology in development and disease
(Kim et al., 2014).
The NC is a transient stem cell popula-
tion that emerges from the dorsal margin
of the neural plate in vertebrate embryos.
During neural tube closure, NC cells
undergo an epithelial to mesenchymal
transition (EMT) and migrate extensively
to populate different parts of the embryo.
In their target structures, they give rise to
a plethora of cell types and tissues, such
as the ectomesenchyme of the craniofa-
cial elements, glia and neurons of the
peripheral nervous system (PNS), mela-
nocytes in the skin, and smooth muscle
cells of the outflow track of the heart.
The existence of cells with NC potential
is not restricted to early embryonic devel-
opment because NC-like cells have been
identified in NC-derived tissues during
the fetal period and adulthood of various
vertebrate species, including human.
Moreover, NC-like cells have been iso-
lated from many sources, such as skin,
sciatic nerve, gut, and bone marrow.
Although they display cell-intrinsic differ-
ences depending on the source andtiming of isolation, postmigratory NC-like
cells are capable of differentiating into
several neural and nonneural cell types.
Therefore, given their broad develop-
mental potential and their accessibility in
adult organs, it has been proposed that
NC-like cells might have therapeutic
value. However, a major limitation for the
use of postmigratory NC-like cells is their
restricted availability and expandability
(Dupin and Sommer, 2012).
Given the broad range of diseases with
NC etiology and the restrictions in the
isolation of human NC, the development
of new model systems for the generation
of this cell population is imperative.
Such models should provide good tools
not only for the study of mechanisms
underlying NC self-renewal and cell fate
specification but also for human disease
modeling. In the last decade, a major
effort has focused on the derivation of
NC cells from human embryonic stem
cells (hESCs) and induced pluripotent
stem cells (iPSCs). Several studies have
reported the differentiation of NC deriva-
tives from hESCs or iPSCs, including
melanocytes, nociceptive neurons, and5, October 2, 2014 ª2014 Elsevier Inc. 397
